Showing results (911-920 of 1,649) with videos related to
Sort By:
Pageof 165
Therapeutic Innovation & Regulatory Science|February 20, 2020
Notable Differences in Drug Lag Between Korea and Japan of New Drugs Between 2009 and 2017Sang-Won Lee, So-Hee Park, Inmyung Song, et al.Therapeutic Innovation & Regulatory Science|February 20, 2020
Exact Unconditional Tests for Dichotomous Data When Comparing Multiple Treatments With a Single ControlGuogen Shan, Carolee Dodge-Francis, Gregory E WildingTherapeutic Innovation & Regulatory Science|February 20, 2020
Exact Confidence Limits on Some New Measures of Concordance and Discordance in Binary OutcomesKung-Jong LuiTherapeutic Innovation & Regulatory Science|February 14, 2020
The Competence and Willingness to Consent to Research Among Patients with Heroin DependenceLiyan Zhao, Hong Shi, Bing Ying, et al.Therapeutic Innovation & Regulatory Science|February 8, 2020
How is the Pharmaceutical Industry Structured to Optimize Pediatric Drug Development? Existing Pediatric Structure Models and Proposed Recommendations for Structural EnhancementThomas Severin, Solange Corriol-Rohou, Christina Bucci-Rechtweg, et al.Therapeutic Innovation & Regulatory Science|October 30, 2019
Improving the Standards of Reporting of Clinical Trial DataJitendra GanjuTherapeutic Innovation & Regulatory Science|December 12, 2018
The Meanings of "Pediatric Drug Development"Klaus Rose, Jane M Grant-KelsTherapeutic Innovation & Regulatory Science|August 15, 2017
Neonatal Safety Information Reported to the FDA During Drug Development StudiesDebbie Avant, Gerri Baer, Jason Moore, et al.Therapeutic Innovation & Regulatory Science|June 28, 2021
Optimising Multi-stakeholder Practices in Patient Engagement: A Gap Analysis to Enable Focused Evolution of Patient Engagement in the Development and Lifecycle Management of MedicinesS D Faulkner, C A C M Pittens, N S Goedhart, et al.Therapeutic Innovation & Regulatory Science|February 2, 2020
Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries AnalysisIraj DaizadehPageof 165